Biocryst Pharmaceuticals, Inc. · NASDAQ:BCRX
Biocryst Pharmaceuticals — Q4 2023 Earnings Presentation
14 slides from Biocryst Pharmaceuticals's earnings presentation, Feb 26, 2024
Slide 1: Fourth Quarter and Full Year 2023 Results Call
Fourth Quarter and Full Year 2023 Results Call Corporate Update & Financial Results February 26, 2024 CONFIDENTIAL & PROPRIETARY
Slide 2: Forward-looking statements
Forward-looking statements BioCryst’s presentation contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks, uncertainties a
Slide 3: Agenda
AGENDA Jon Stonehouse Corporate update President and Chief Executive Officer Dr. Ryan Arnold Chief Medical Officer ORLADEYO® update Charlie Gayer Chief Commercial Officer Anthony Doyle Financial update Chief Financial Officer Q&A 3
Slide 4: Patients experience excellent HAE control on ORLADEYO
Patients experience excellent HAE control on ORLADEYO LONG-TERM CLINICAL EVIDENCE LONG-TERM REAL-WORLD EVIDENCE 90.8% Rapid Sustained Attack reduction vs baseline after 96 Rapid attack control regardless of Sustained attack control regardless weeks on berotralstat 150mg in baseline rate or C1-INH le
Slide 5: ORLADEYO reduced attacks by 90.8% compared to baseline after 96 weeks
ORLADEYO reduced attacks by 90.8% compared to baseline after 96 weeks • Final published analysis of 96- MONTHLY ATTACK RATE REDUCTION week data from the APeX-2 trial showed patients who received berotralstat 150 mg from Day 1 experienced an average reduction in monthly attack rate of 90.8% compared
Slide 6: Reduced attack rates, regardless of baseline attacks
Reduced attack rates, regardless of baseline attacks MEDIAN MONTHLY ATTACK RATE PROGRESSION BY BASELINE RATE • Patients experienced rapid, substantial and sustained reductions in attacks after starting ORLADEYO, regardless of baseline attack rate • Patients with zero attacks at baseline maintained a
Slide 7: Sustained attack control, regardless of prior prophy
Sustained attack control, regardless of prior prophy • Patients experienced sustained median MEDIAN MONTHLY ATTACK RATE BY PRIOR PROPHYLAXIS attack rates of approximately 0.5 per month on ORLADEYO, regardless of prior prophylaxis therapy Source: Consistently low hereditary angioedema attack rates wi
Slide 8: Reduced attack rates, regardless of C1-INH level and function
Reduced attack rates, regardless of C1-INH level and function • Patients who initiated ORLADEYO MONTHLY ATTACK RATE BY C1-INH DEFICIENCY experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of their C1-inhibitor (C1- INH) level and functio
Slide 9: Historically, patients on injectable prophylaxis report low but consistent attack rates
Historically, patients on injectable prophylaxis report low but consistent attack rates MEAN # OF ATTACKS IN PAST 3 MONTHS (2018-2019 PATIENT SURVEY DATA) • Patients taking injectable prophylaxis therapies have reported mean attack rates in the range of 0.3 to 0.6 per month Source: Hereditary Angioe
Slide 10: Approved label: ORLADEYO (berotralstat) safety
Approved label: ORLADEYO (berotralstat) safety In APeX-2 (part 1), the most common treatment-emergent adverse reactionsa were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease (GERD) Findings from the open-label, long-term safety study, APeX-S (interim safety popul
Slide 11: Market research: Intent to prescribe more ORLADEYO remains consistent
MARKET RESEARCH: Intent to prescribe more ORLADEYO remains consistent, with prescriptions coming mostly from prophylactic switches ALLERGIST-IMMUNOLOGISTS (A/IS) PRESCRIBING - 2023 SOURCE OF FUTURE NEW ORLADEYO PRESCRIPTIONS - 2024 (n=154 unique A/Is managing ~1,300 HAE patients) (n=154 unique A/Is
Slide 12: Path to $800M US revenue in 2029
Path to $800M US revenue in 2029 Modest average price increases 2024-2029 Improve rate of ~200 annual net Paid to 85% ASSUMPTIONS patients added, 2024-2029 • 15-20% gross-to-net on Paid shipments • Compliance in low-90s% ~1,050 Paid + PAP* patients * PAP is the company’s long-term patient with 73% P
Slide 13: Finance summary
Finance summary (FIGURES IN MILLIONS) Q4 2023 CASH POSITION Cash, cash equivalents, restricted cash & investments at December 31, 2022 $444 Cash, cash equivalents, restricted cash & investments at December 31, 2023 $391 Senior credit facilityA $314 2024 FY GUIDANCE ORLADEYO revenue $380-400 Operatin
Slide 14: Fourth Quarter and Full Year 2023 Results Call
Fourth Quarter and Full Year 2023 Results Call Corporate Update & Financial Results February 26, 2024 CONFIDENTIAL & PROPRIETARY
BioCryst Pharmaceuticals — Q4 2023 Earnings Presentation on 6ix